Joseph M. Connors, MD from British Colombia Cancer Agency discusses results of the Echelon-1 Trial and new chemotherapy that is a combination of brentuximab vedotin, and AVD at the 2017 American Society of Hematology.
Results of the Echelon-1 Trial New chemotherapy is a combination of brentuximab vedotin, and AVD
